Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 7, 2007

Multibillion-Dollar Depression Market Gets Crowded

  • With the expiration of Teva Pharmaceuticals’ 180-day market exclusivity on its generic version of Pfizer’s blockbuster depression drug, four companies are ready to enter this multibillion-dollar market.

    Zoloft, indicated for depression and certain types of anxiety disorders, had U.S. sales of approximately $2.9 billion for the 12-month period ending Dec. 31, 2006, according to IMS Health. In 2005, Pfizer’s last full year on the market, sales reached $3.5 billion.

    Mylan Pharmaceuticals, Pliva, Actavis Group, and Lupin Pharmaceuticals each received approval for sertraline hydrochloride tablets, 25 mg, 50 mg, and 100 mg.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »